Paul Gulbas, MD
Ophthalmology · Ruidoso, NMNPI 1376552810
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $8,760 of the $13,736 with a category attached, or 63.8%. Sight Sciences, Inc. accounts for 63.8% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2019 at $9,211 and has fallen 83.2% since, to $1,552 in 2025. Among ophthalmology clinicians in NM with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 226 payments — averaging $60.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sight Sciences, Inc.$9K
- AbbVie$2K
- Nova Eye, Inc.$785
- Alcon$436
- Aerie Pharmaceuticals, Inc.$372
- Novartis$274
- plus $1K from 13 others
Across 33 payments — averaging $9400.17 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Glaukos Corporation$215K
- Sight Sciences, Inc.$95K
What the payments were for
- Consulting fees$8,76064%
- Food & beverage$4,97636%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sight Sciences, Inc. | 8 | $8,760 |
| AbbVie(2 entities) | 95 | $2,109 |
| Nova Eye, Inc. | 1 | $785 |
| Alcon | 27 | $436 |
| Aerie Pharmaceuticals, Inc. | 23 | $372 |
| Novartis | 26 | $274 |
| Carl Zeiss Meditec USA, Inc. | 4 | $207 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 11 | $184 |
| Bausch & Lomb Americas Inc. | 8 | $151 |
| Harrow Eye, LLC | 3 | $99 |
| Johnson & Johnson Surgical Vision, Inc. | 4 | $73 |
| Kala Pharmaceuticals, Inc. | 3 | $55 |
| Biotissue Holdings Inc. | 3 | $52 |
| Sun Pharmaceutical Industries Inc. | 3 | $51 |
| Tarsus Pharmaceuticals, Inc. | 2 | $40 |
| Genmab U.S., Inc. | 1 | $32 |
| Rxsight Inc | 2 | $26 |
| Oyster Point Pharma, Inc. | 1 | $16 |
| Eyevance Pharmaceuticals LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OMNI$8,760
- VERACITY SURGICAL$160
How this compares
$13,736 in reported general payments places this provider in the 95th percentile of 81 ophthalmology providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 49 | $65,610 |
| RhopressaNetarsudil Mesylate | 95 | $53,401 |
| LumiganBimatoprost | 83 | $47,944 |
| XiidraLifitegrast | 34 | $35,344 |
| RocklatanNetarsudil Mesylat/Latanoprost | 33 | $21,429 |
| CombiganBrimonidine Tartrate/Timolol | 48 | $20,554 |
| VyzultaLatanoprostene Bunod | 37 | $18,147 |
| Cyclosporine | 20 | $17,612 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 103 | $15,204 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 35 | $11,597 |
| Latanoprost | 810 | $8,542 |
| Prednisolone Acetate | 236 | $8,429 |
| Brimonidine Tartrate | 223 | $6,251 |
| Travoprost | 53 | $5,891 |
| MoxifloxacinMoxifloxacin Hcl | 172 | $5,657 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $2,109 | $134,108180 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $372 | $74,830128 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $151 | $53,49171 claims |
| AlconSimbrinza | $436 | $11,59735 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 81 ophthalmology providers in New Mexico.
Other ophthalmology in Ruidoso
- Mark GallardoLas Cruces$1.2M
- Robert MelendezAlbuquerque$349K
- John PitcherAlbuquerque$307K
- Christopher RoybalAlbuquerque$51K
- Stephen ColemanAlbuquerque$12K
- Rachel DavisAlbuquerque$10K
- Ian ThompsonAlbuquerque$10K
- Paul SanchezAlbuquerque$8K
- Iuri GolubevAlbuquerque$7K
- Parley FillmoreAlamogordo$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.